KANAPH THERAPEUTICS

Kanaph Therapeutics is a biotech with activities that range from drug discovery to early-stage clinical trials. We are dedicated to developing next-generation therapeutics for oncology and autoimmune diseases. Our oncology pipeline includes bi-specific antibodies and small molecules that have a greatly enhanced immuno-stimulatory activity in the tumor microenvironment (TME) for efficient tumor eradication. Our autoimmune disease pipeline is composed of bispecific Fc-fusions that inhibit the alternative complement pathway while inhibiting angiogenesis and downstream complement activation as well.